Abstract
This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.
| Original language | English |
|---|---|
| Pages (from-to) | 233-237 |
| Number of pages | 5 |
| Journal | Journal of Clinical Pathology |
| Volume | 57 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pathology and Forensic Medicine
Cite this
Updated recommendations for HER2 testing in the UK. / Ellis, I. O.; Bartlett, J.; Dowsett, M.; Humphreys, S.; Jasani, B.; Miller, K.; Pinder, S. E.; Rhodes, A.; Walker, R.
In: Journal of Clinical Pathology, Vol. 57, No. 3, 03.2004, p. 233-237.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Updated recommendations for HER2 testing in the UK
AU - Ellis, I. O.
AU - Bartlett, J.
AU - Dowsett, M.
AU - Humphreys, S.
AU - Jasani, B.
AU - Miller, K.
AU - Pinder, S. E.
AU - Rhodes, A.
AU - Walker, R.
PY - 2004/3
Y1 - 2004/3
N2 - This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.
AB - This paper serves to update previously published guidance on rationale and methodology for HER2 laboratory testing following the recommendation for the use of HER2 targeted treatment in the management of advanced breast cancer in the UK. Emphasis is placed on the standardisation of methodology and assessment and strategies to achieve high quality performance. A two phase testing algorithm based on first line immunocytochemistry evaluation and second line fluorescence in situ hybridisation assessment of borderline cases is recommended. To ensure maintenance of expertise, an annual caseload volume of at least 250 cases is recommended for laboratories providing a testing service.
UR - http://www.scopus.com/inward/record.url?scp=1542511907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1542511907&partnerID=8YFLogxK
U2 - 10.1136/jcp.2003.007724
DO - 10.1136/jcp.2003.007724
M3 - Article
VL - 57
SP - 233
EP - 237
JO - Journal of Clinical Pathology - Clinical Molecular Pathology
JF - Journal of Clinical Pathology - Clinical Molecular Pathology
SN - 0021-9746
IS - 3
ER -